JP7080878B2 - タンパク質界面 - Google Patents

タンパク質界面 Download PDF

Info

Publication number
JP7080878B2
JP7080878B2 JP2019514203A JP2019514203A JP7080878B2 JP 7080878 B2 JP7080878 B2 JP 7080878B2 JP 2019514203 A JP2019514203 A JP 2019514203A JP 2019514203 A JP2019514203 A JP 2019514203A JP 7080878 B2 JP7080878 B2 JP 7080878B2
Authority
JP
Japan
Prior art keywords
peptide
rad51
cell
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019514203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527066A5 (enExample
JP2019527066A (ja
Inventor
チャーリー チャーワン，
マリア ソロヴェイチク，
Original Assignee
シンセックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンセックス， インコーポレイテッド filed Critical シンセックス， インコーポレイテッド
Publication of JP2019527066A publication Critical patent/JP2019527066A/ja
Publication of JP2019527066A5 publication Critical patent/JP2019527066A5/ja
Priority to JP2022084997A priority Critical patent/JP7479421B2/ja
Application granted granted Critical
Publication of JP7080878B2 publication Critical patent/JP7080878B2/ja
Priority to JP2024070016A priority patent/JP2024099695A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/85—Saccharomyces
    • C12R2001/865—Saccharomyces cerevisiae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
JP2019514203A 2016-05-27 2017-05-26 タンパク質界面 Active JP7080878B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022084997A JP7479421B2 (ja) 2016-05-27 2022-05-25 タンパク質界面
JP2024070016A JP2024099695A (ja) 2016-05-27 2024-04-23 タンパク質界面

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662342840P 2016-05-27 2016-05-27
US62/342,840 2016-05-27
US201662384226P 2016-09-07 2016-09-07
US62/384,226 2016-09-07
PCT/US2017/034870 WO2017205852A2 (en) 2016-05-27 2017-05-26 Protein interfaces

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022084997A Division JP7479421B2 (ja) 2016-05-27 2022-05-25 タンパク質界面

Publications (3)

Publication Number Publication Date
JP2019527066A JP2019527066A (ja) 2019-09-26
JP2019527066A5 JP2019527066A5 (enExample) 2020-07-02
JP7080878B2 true JP7080878B2 (ja) 2022-06-06

Family

ID=60411842

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019514203A Active JP7080878B2 (ja) 2016-05-27 2017-05-26 タンパク質界面
JP2022084997A Active JP7479421B2 (ja) 2016-05-27 2022-05-25 タンパク質界面
JP2024070016A Pending JP2024099695A (ja) 2016-05-27 2024-04-23 タンパク質界面

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022084997A Active JP7479421B2 (ja) 2016-05-27 2022-05-25 タンパク質界面
JP2024070016A Pending JP2024099695A (ja) 2016-05-27 2024-04-23 タンパク質界面

Country Status (9)

Country Link
US (4) US10188691B2 (enExample)
EP (2) EP3463414B1 (enExample)
JP (3) JP7080878B2 (enExample)
CN (2) CN109562138B (enExample)
AU (4) AU2017271678B2 (enExample)
BR (1) BR112018074472A2 (enExample)
CA (1) CA3025423A1 (enExample)
MX (2) MX2018014366A (enExample)
WO (1) WO2017205852A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018014366A (es) 2016-05-27 2019-04-11 Synthex Inc Interfaces de proteina.
WO2019099678A1 (en) 2017-11-16 2019-05-23 Synthex, Inc. Selective modulation of protein-protein interactions
WO2019104244A1 (en) 2017-11-22 2019-05-31 Synthex, Inc. Peptides for inhibiting rad51
CN114401730A (zh) * 2019-05-01 2022-04-26 因内特生物制品有限责任公司 免疫调节组合物和方法
WO2020232343A1 (en) 2019-05-15 2020-11-19 Synthex, Inc. Selective degradation of proteins
JP2023145812A (ja) * 2020-08-17 2023-10-12 国立大学法人東海国立大学機構 人工タンパク質、Ｒａｓ阻害剤及び抗がん剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505418A (ja) 1996-11-05 2001-04-24 レキシコン ジェネティックス インコーポレーテッド 細胞増殖を阻害するための哺乳動物Ｒａｄ５１タンパク質の破壊及び哺乳動物Ｒａｄ５１に関連するタンパク質の破壊

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11502717A (ja) 1995-04-11 1999-03-09 ザ ジェネラル ホスピタル コーポレーション 逆ツーハイブリッドシステム
US5733726A (en) 1995-06-07 1998-03-31 Emory University Cytotoxicity-based genetic selection system (TOXSEL)
WO1998007845A1 (en) 1996-08-23 1998-02-26 President And Fellows Of Harvard College Interaction trap assay, reagents and uses thereof
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
CA2417135C (en) 1997-11-19 2005-04-12 Microbia, Inc. Chimeric pre-activated transcription factors
WO1999025735A1 (en) 1997-11-19 1999-05-27 Microbia, Inc. Chimeric pre-activated transcription factors
US6303302B1 (en) 1997-11-19 2001-10-16 The Whitehead Institute For Biomedical Research Regulation of fungal gene expression
DE69935313T2 (de) 1998-01-09 2007-11-15 Phylogica Ltd., Northbridge Nachweisverfahren für peptide
IL138353A0 (en) 1998-03-26 2001-10-31 Glaxo Group Ltd Assay methods
US6332897B1 (en) 1998-03-27 2001-12-25 Glaxo Wellcome Inc. Assay methods
US6316223B1 (en) 1998-03-30 2001-11-13 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system
US6114111A (en) 1998-03-30 2000-09-05 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system
DE19901008A1 (de) * 1999-01-13 2000-07-20 Deutsches Krebsforsch Peptide zur Inhibierung von HPV E6-Proteinen
WO2000053630A2 (en) 1999-03-09 2000-09-14 Lexicon Genetics Incorporated COMPOUNDS THAT DISRUPT MAMMALIAN Rad51 ACTIVITY
US7270969B2 (en) * 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
DE60043889D1 (en) 1999-06-07 2010-04-08 Tet Systems Holding Gmbh & Co Tet repressor basierte transkriptionale regulatorische proteine
US6790607B1 (en) 1999-10-07 2004-09-14 Hybrigen, Inc. Adjustable sensitivity, genetic molecular interaction systems, including protein-protein interaction systems for detection and analysis
JP2004500805A (ja) 1999-10-07 2004-01-15 ハイブリジェン、インコーポレイテッド 検出および分析のためのタンパク質−タンパク質相互作用系を含む調整可能な感度の遺伝子的分子相互作用系
US20020086840A1 (en) 2000-01-26 2002-07-04 Zarling David A. Use of Rad51 inhibitors for p53 gene therapy
US7252952B2 (en) 2000-03-06 2007-08-07 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein—protein interaction
US7105341B2 (en) 2000-03-06 2006-09-12 Rigel Pharmaceuticals. Inc. In vivo production of cyclic peptides
US7566765B2 (en) 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
US7378248B2 (en) 2000-03-06 2008-05-27 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein-protein interaction
AU2001245584B2 (en) 2000-03-08 2007-02-08 Phylogica Limited Improved reverse n-hybrid screening method
US20030211495A1 (en) 2000-03-08 2003-11-13 Richard Hopkins Reverse n-hybrid screening method
WO2001066787A1 (en) 2000-03-08 2001-09-13 Tvw Telethon Institute For Child Health Research Improved reverse n-hybrid screening method
GB0006572D0 (en) 2000-03-17 2000-05-10 Isis Innovation Novel transcription transactivator protein
AU2001283226A1 (en) 2001-08-09 2003-02-24 Pangene Corporation Methods and compositions for inhibiting rad51
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
AU2003279461A1 (en) * 2002-11-07 2004-06-07 Imperial College Innovations Limited Disorders of lipid metabolism
JP2004215624A (ja) * 2003-01-17 2004-08-05 Celestar Lexico-Sciences Inc 相互作用インヒビターの検出方法、相互作用インヒビターライブラリーおよびインヒビター検出キット
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
JP2005095613A (ja) 2003-09-04 2005-04-14 Taiyo Parts Kk 昇降装置
CN1905864B (zh) * 2003-12-01 2011-04-06 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
JPWO2005095613A1 (ja) 2004-03-30 2008-02-21 ジェノミディア株式会社 Ｒａｄ５１の発現抑制剤、該発現抑制剤を有効成分として含む医薬、及びその使用
EP1810028A2 (en) 2004-10-14 2007-07-25 Rigel Pharmaceuticals, Inc. Heterocyclic inhibitors of ires-mediated translation and methods of use thereof
JP2010514777A (ja) 2006-12-26 2010-05-06 ファーマサイクリックス，インク． 併用療法においてヒストンデアセチラーゼ阻害剤を使用し、バイオマーカーをモニタする方法
US8759089B2 (en) 2007-02-06 2014-06-24 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US7892823B2 (en) 2007-02-06 2011-02-22 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US8105493B2 (en) 2007-06-29 2012-01-31 Jnc Corporation Aggregation and dispersion methods of magnetic particles, separation and detection methods using the same and detection kit
US8597949B2 (en) 2007-07-28 2013-12-03 The University Of Chicago Methods and compositions for modulating RAD51 and homologous recombination
US9273100B2 (en) 2007-11-09 2016-03-01 Board Of Trustees Of Michigan State University Use of Galerina marginata genes and proteins for peptide production
US9518097B2 (en) 2007-11-09 2016-12-13 Board Of Trustees Of Michigan State University Identification and use of genes encoding amatoxin and phallotoxin
WO2012019157A2 (en) 2010-08-06 2012-02-09 The Regents Of The University Of California Expression and purification of fusion protein with multiple mbp tags
US9249410B2 (en) 2010-12-15 2016-02-02 The Johns Hopkins University Two-hybrid based screen to identify disruptive residues at multiple protein interfaces
US10912761B2 (en) 2012-11-30 2021-02-09 The University Of Chicago Methods and compositions involving RAD51 inhibitors
WO2015138377A1 (en) 2014-03-10 2015-09-17 The University Of Chicago Methods of treating cancer using rad51small molecule stimulators
US10421753B2 (en) 2015-03-02 2019-09-24 The Regents Of The University Of California RAD51 inhibitors and uses thereof
MX2018014366A (es) 2016-05-27 2019-04-11 Synthex Inc Interfaces de proteina.
WO2019099678A1 (en) 2017-11-16 2019-05-23 Synthex, Inc. Selective modulation of protein-protein interactions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505418A (ja) 1996-11-05 2001-04-24 レキシコン ジェネティックス インコーポレーテッド 細胞増殖を阻害するための哺乳動物Ｒａｄ５１タンパク質の破壊及び哺乳動物Ｒａｄ５１に関連するタンパク質の破壊

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MYUN HWA DUNLOP，MECHANISTIC INSIGHTS INTORAD51-ASSOCIATED PROTEIN 1(RAD51AP1) ACTION IN HOMOLOGOUS DNA REPAIR，THE JOURNAL OF BIOLOGICAL CHEMISTRY，2012年04月06日，VOL. 287, NO. 15，PAGE(S):12343-12347，https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320983/pdf/zbc12343.pdf
OLEG V. KOVALENKO，A NOVEL NUCLEIC ACID-BINDING PROTEIN THAT INTERACTS WITH HUMAN RAD51 RECOMBINASE，NUCLEIC ACIDS RESEARCH，1997年12月15日，VOL. 25, NO. 24，PAGE(S):4946-4953，https://www.ncbi.nlm.nih.gov/pmc/articles/PMC147164/pdf/254946.pdf

Also Published As

Publication number Publication date
EP4269427A2 (en) 2023-11-01
CN109562138B (zh) 2023-03-21
US20210252100A1 (en) 2021-08-19
BR112018074472A2 (pt) 2019-03-19
EP3463414A2 (en) 2019-04-10
AU2017271678A1 (en) 2018-12-13
US20250177474A1 (en) 2025-06-05
EP4269427A3 (en) 2023-11-22
JP2024099695A (ja) 2024-07-25
US20190216879A1 (en) 2019-07-18
JP2022119883A (ja) 2022-08-17
JP7479421B2 (ja) 2024-05-08
MX2023002591A (es) 2024-02-08
EP3463414A4 (en) 2019-10-23
AU2021205010A1 (en) 2021-08-05
CA3025423A1 (en) 2017-11-30
MX2018014366A (es) 2019-04-11
EP3463414B1 (en) 2023-09-13
AU2022259709A1 (en) 2022-11-24
WO2017205852A3 (en) 2018-01-25
CN116217657A (zh) 2023-06-06
WO2017205852A2 (en) 2017-11-30
CN109562138A (zh) 2019-04-02
AU2017271678B2 (en) 2021-05-06
US12214008B2 (en) 2025-02-04
EP3463414C0 (en) 2023-09-13
AU2024204362A1 (en) 2024-07-11
US10188691B2 (en) 2019-01-29
US20170368132A1 (en) 2017-12-28
AU2021205010B2 (en) 2022-08-11
JP2019527066A (ja) 2019-09-26

Similar Documents

Publication Publication Date Title
JP7479421B2 (ja) タンパク質界面
CN110194787B (zh) 靶向抑制Wnt/β-catenin信号活性的多肽及其用途
US20240018188A1 (en) Compounds for selective disruption of protein-protein interactions
TW201000116A (en) Peptide compound and use thereof
AU2025205399A1 (en) Compositions for use in lysis of selective cancer cells
US12281180B2 (en) Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same
HK40007101A (en) Protein interfaces
HK40007101B (en) Protein interfaces
CN114222576A (zh) 治疗癌症的方法
Zhao et al. Sentrin/SUMO-specific protease 1 contributes to drug resistance in melanoma by mediating the deSUMOylation of Yes-associated protein
US9145554B2 (en) Cancer therapy method
HK40069081A (en) Methods of treating cancer
WO2019043279A1 (es) Composiciones capaces de modular la estimulación de gdnf endógeno para el tratamiento de enfermedades neurodegenerativas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220425

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220525

R150 Certificate of patent or registration of utility model

Ref document number: 7080878

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250